论文部分内容阅读
目的探讨文拉法辛在慢性阻塞性肺疾病伴焦虑抑郁治疗中的临床应用前景。方法将我院于2012年1月~2013年12月收住的86例慢性阻塞性肺疾病(COPD)合并焦虑抑郁患者随机分为对照组和试验组,每组各43例。对照组采取常规治疗,试验组在对照组常规基础上加用文拉法辛治疗。治疗4周后,对比两组患者的肺功能、生活质量、负性情绪及不良反应。结果通过4周治疗,试验组患者FEV1占预计值和FEV1/FVC显著高于对照组(P<0.01),SGRQ、HAMA、HAMD评分明显低于对照组(P<0.01),两组之间的不良反应发生率无统计学差异(P>0.05)。结论文拉法辛能明显改善COPD患者的焦虑及抑郁症状,提高患者生活质量,可在临床推广应用。
Objective To investigate the clinical application of venlafaxine in the treatment of chronic obstructive pulmonary disease with anxiety and depression. Methods Eighty-six patients with chronic obstructive pulmonary disease (COPD) admitted to our hospital from January 2012 to December 2013 with anxiety and depression were randomly divided into control group and trial group, with 43 cases in each group. The control group to take conventional treatment, the experimental group in the control group on the basis of conventional plus venlafaxine treatment. After 4 weeks of treatment, lung function, quality of life, negative emotions and adverse reactions were compared between the two groups. Results After 4 weeks of treatment, FEV1 and FEV1 / FVC in the experimental group were significantly higher than those in the control group (P <0.01), and the scores of SGRQ, HAMA and HAMD in the experimental group were significantly lower than those in the control group (P <0.01) No significant difference in the incidence of adverse reactions (P> 0.05). Conclusion Venlafaxine can significantly improve the symptoms of anxiety and depression in patients with COPD and improve the quality of life of patients, which can be popularized and applied clinically.